Live
- BJP releases ‘charge sheet’ against BJD govt
- District Nodal Officer Venkataramana announced the intermediate results
- She team that stopped child marriages
- Medical devices sector needs separate rules, says industry body AiMeD
- Andhra Paper declares lockout
- Opposition INDIA bloc working on 'one year, one PM' formula: PM Modi
- Delhi HC quashes FIR for outraging woman's modesty, orders man to assist Traffic Police for a month as settlement
- 'Apologise to families of farmers who committed suicide in Vidarbha', Amit Shah dares Sharad Pawar
- SC Collegium recommends appointment of a permanent judge in Chhattisgarh HC, extension of term of two judges
- U20 Men's football nationals: Telangana, Sikkim earn full points with easy win
Natco settles patent litigation with Onyx
Highlights
City-based Natco Pharma on Thursday said it has settled a patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug.
Hyderabad: City-based Natco Pharma on Thursday said it has settled a patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug.
The company said it has reached a settlement agreement with Onyx Therapeutics Inc related to generic versions of 10mg, 30mg and 60mg of Kyprolis, Natco Pharma said in a regulatory filing.
Natco has tied up with Breckenridge Pharmaceutical Inc to market the product in the US.
Next Story
ADVERTISEMENT
